Ifinatamab Deruxtecan

Summary

Ifinatamab Deruxtecan (CHEMBL5095331) is a phase-3 clinical-stage antibody drug conjugate targeting CD276; indicated across 3 conditions including small cell lung carcinoma and neoplasm.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody drug conjugate
• Targets: 1 (CD276)
• Indications: 3 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5095331
Name	Ifinatamab Deruxtecan
Type	Antibody drug conjugate
Max phase	3

Also known as: Ds 7300a, DS-7300A, DS7300A, Ifinatamab deruxtecan, Mabx-9001a cysteinyl-deruxtecan, IFINATAMAB DERUXTECAN

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
CD276	B7-H3 (CD276)	Binding		4%	Q5ZPR3

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

Aggregated over 1 target gene(s): CD276.

Dominant GO biological processes

GO term	Targets
regulation of cytokine production	1
positive regulation of type II interferon production	1
positive regulation of T cell proliferation	1
T cell activation	1
regulation of immune response	1
T cell receptor signaling pathway	1
positive regulation of cytokine production	1
regulation of type II interferon production	1

Indications & clinical

Indications

3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
small cell lung carcinoma	3	MONDO:0008433	EFO:0000702
neoplasm	2	MONDO:0005070	EFO:0000616
lung neoplasm	1	MONDO:0021117	MONDO:0008903

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	3
PHASE2	2
PHASE1/PHASE2	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06203210	PHASE3	RECRUITING	A Study of Ifinatamab Deruxtecan Versus Treatment of Physician’s Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06644781	PHASE3	RECRUITING	A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
NCT06925737	PHASE3	RECRUITING	A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
NCT06330064	PHASE2	RECRUITING	A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
NCT06362252	PHASE1/PHASE2	RECRUITING	A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
NCT06780085	PHASE2	RECRUITING	A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
NCT06863272	PHASE1/PHASE2	RECRUITING	A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
NCT07535359	Not specified	AVAILABLE	Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).